Transgene Biotek Limited (BOM:526139)

India flag India · Delayed Price · Currency is INR
2.880
+0.010 (0.35%)
At close: Apr 28, 2026
-24.61%
Market Cap 218.22M
Revenue (ttm) 2.33M
Net Income (ttm) -19.09M
Shares Out 75.77M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 34,593
Average Volume 47,408
Open 2.890
Previous Close 2.870
Day's Range 2.720 - 2.890
52-Week Range 1.830 - 5.260
Beta 0.72
RSI 55.80
Earnings Date May 26, 2026

About Transgene Biotek

Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. T... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Country India
Stock Exchange Bombay Stock Exchange
Ticker Symbol 526139
Full Company Profile

Financial Performance

In fiscal year 2025, Transgene Biotek's revenue was 2.61 million, an increase of 10.98% compared to the previous year's 2.35 million. Losses were -6.76 million, 3.14% more than in 2024.

Financial Statements

News

There is no news available yet.